ImmunoGen (NASDAQ:IMGN) has tumbled 33.07% during the past week and has dropped 40.4% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 32.26%. ImmunoGen (NASDAQ:IMGN) has underperformed the index by 40.94% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
ImmunoGen (NASDAQ:IMGN): The stock opened at $3.52 on Friday but the bulls could not build on the opening and the stock topped out at $3.52 for the day. The stock traded down to $3.29 during the day, due to lack of any buying support eventually closed down at $3.32 with a loss of -4.87% for the day. The stock had closed at $3.49 on the previous day. The total traded volume was 3,257,099 shares.
The company shares have dropped -77.31% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $19.43 and the one year low was seen on Jun 17, 2016. The 50-Day Moving Average price is $5.54 and the 200 Day Moving Average price is recorded at $8.59.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Lambert John, officer (Executive Vice President) of Immunogen Inc, had unloaded 3,889 shares at an average price of $8.22 in a transaction dated on February 1, 2016. The total value of the transaction was worth $31,968.
Many analysts have stated their opinion on the company shares. Brokerage firm RBC Capital downgrades its rating on ImmunoGen (NASDAQ:IMGN). The shares have been rated Sector Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 2, 2016. Currently the company Insiders own 4.2% of ImmunoGen shares according to the proxy statements. Institutional Investors own 86.74% of ImmunoGen shares. During last six month period, the net percent change held by insiders has seen a change of -9.48%.
ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.